We are live on ! Find out more

SRX Global

SRXH

Market cap $17.8M

0.8800 USD

-0.0630

6.68%

At close Updated Nov 11, 4:00 PM EST

Pre-market

After hours

0.8808

+0.0008

0.09%

1 day

-6.68%

5 days

1 month

-35.29%

3 months

-52.17%

6 months

-87.78%

Year to date

-93.83%

1 year

-93.37%

5 years

-99.99%

10 years

-99.99%

About: SRX Global Inc is an AI-driven platform focused on investing in operating companies, strategic assets, and technology-enabled opportunities across multiple sectors. It uses technology and data analytics to identify and manage investments.

Employees: 11

Consumer Staples Beverages - Non-Alcoholic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Neutral

GlobeNewsWire

12 days ago

SRX Global Provides Update on Balance Sheet and Share Buyback

NORTH PALM BEACH, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today is providing shareholders with an update on its balance sheet and share buyback.

Neutral

GlobeNewsWire

16 days ago

SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics' Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

UC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment capacity and streamline treatment logistics

Neutral

GlobeNewsWire

1 month ago

SRX Global Commits $2.5 Million to Launch Multi-Strategy Trading Platform in Partnership with 5T Trading, Powered by the EMJX Platform

New platform to be launched with managers from Millennium Management, Balyasny and Citadel, designed to enable the next generation of proprietary traders under Eric Jackson's leadership New platform to be launched with managers from Millennium Management, Balyasny and Citadel, designed to enable the next generation of proprietary traders under Eric Jackson's leadership

Neutral

GlobeNewsWire

1 month ago

SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies

SPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders Proposed acquisition expected to accelerate development of CERo's lead product candidate, CER-1236, for hematologic malignancies NORTH PALM BEACH, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has entered into definitive purchase agreement under which CERo Therapeutics, the operating subsidiary of CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo Holdings" and, together with CERo Therapeutics, "CERo"), an innovative cellular immunotherapy company advancing the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, will become a wholly owned subsidiary of SRX Global.

Neutral

GlobeNewsWire

1 month ago

SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim

SRX to dividend ETF holdings to shareholders Initial ETF to feature an actively managed digital asset hedging strategy powered by EMJX's proprietary AI technology NORTH PALM BEACH, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced a $1.5 million commitment to launch a new family of actively managed Exchange Traded Funds (ETFs) through its EMJX platform, marking the first step in bringing EMJX's proprietary AI-driven investment intelligence to the broader investing public.

Neutral

GlobeNewsWire

1 month ago

SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)

SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for facial recognition to body cameras. SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for facial recognition to body cameras.

Neutral

GlobeNewsWire

1 month ago

SRX Global CEO Kent Cunningham and President of EMJX Platform Eric Jackson to Present at Webull Corporate Connect Series Fintech Investment Webinar

NORTH PALM BEACH, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that SRX Global's CEO, Kent Cunningham, and President, EMJX Platform and Head of Asset Management, Eric Jackson, will present at the Webull Corporate Connect Series Fintech Investment Webinar, a live investor webinar hosted on the Webull platform, on September 30, 2026.

Neutral

GlobeNewsWire

2 months ago

SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense Company

NORTH PALM BEACH, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today is providing shareholders with an update on its portfolio company ARMR Sciences (“ARMR”), a clinical-stage biodefense company developing a platform of medical countermeasures against synthetic drugs, such as fentanyl, from its CEO, Collin Gage.

Neutral

GlobeNewsWire

2 months ago

SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers

The Debt investment is expected to accelerate development of CERo's lead therapeutic CER-1236 for hematological cancers The Debt investment is expected to accelerate development of CERo's lead therapeutic CER-1236 for hematological cancers

Neutral

GlobeNewsWire

3 months ago

SRX Global Inc. Announces Fiscal Third Quarter 2026 Financial Results

Net Asset Value ("NAV") of $62.9 million , or $3.22 per Common Share, Exceeding Preliminary Estimate of $3.07 per Share 1 Ended the Quarter with $36.7 million of Cash, Cash Equivalents and Restricted Cash, $65.2 million in Current Assets, and $2.4 million in Total Liabilities, With No Debt Outstanding Adjusted EBITDA Loss Improved 35% year over year to $1.6 million 4 Strengthened Halo Operations, Exiting the Quarter with 98% Fill Rates and Record Prime Day Performance NORTH PALM BEACH, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced its financial results for the fiscal third quarter ended June 30, 2026.

See News Rankings

Price charts implemented using Lightweight Charts™

SRX Global SRXH Market cap $17.8M

News

SRX Global

SRXH

Market cap $17.8M